Healthy volunteers (n=20; age 26.5±3.2 years; BMI 22.0±2.7 kg/m2) served as ASQ controls. Results: CAP and 1H-MRS could be applied in 47 (94%) and 48 (96%) diabetic patients, respectively. ASQ was available in all subjects. The ASQ FD ratio correlated with CAP and 1H-MRS values (r=-0.74, p<0.001, and r=-0.3, p=0.008) and was significantly reduced in cases with increased hepatic fat content (fig. 1). Sensitivity and specificity for detection of advanced ste-atosis was 96.9% and 77.8% (CAP >300 dB/m) and 93.1% and 71.4% (1H-MRS >10% lipid concentration) at a FD ratio cut-off of 0.092, respectively. Conclusion: ASQ is a promising method for non-invasive liver fat quantification and should be further

evaluated in biopsy controlled studies. ASQ vs. CAP and 1H-MRS Disclosures: Thomas Karlas – Grant/Research Support: Echosens, Paris, France The following people have nothing to disclose: Stem Cell Compound Library Joachim Berger, Nikita Gar-nov, Franziska Lindner, Harald Busse, Rima Chakaroun, Bettina Relke, Michael Tröltzsch, Volker Keim, Johannes Wiegand Introduction: While non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in developed

countries, currently there is a paucity of effective pharmacologic therapies available for those with non-alcoholic steatohepatitis (NASH), who are at risk of progression to cirrhosis. Animal studies have reported vitamin D supplementation and phototherapy to improve liver histology in diet-induced NASH. We therefore assessed the impact of high-dose oral vitamin D3 supplementation AUY-922 clinical trial on liver histology in a pilot cohort of non-cirrhotic patients with biopsy-proven NASH. Methods: 12 non-cirrhotic patients with NASH,

established MCE公司 by liver biopsy within three months and defined as a NAFLD Activity Score (NAS) of 4 or more, were given high dose oral vitamin D3 supplementation (25,000 IU/ week) for 24 weeks. Dose was titrated every 6 weeks to a target 25-hydroxyvitamin D level of 100-125 nmol/L and repeat liver biopsy was performed at the end of therapy. Baseline and follow up testing of routine biochemistry, homeostatic model-insulin resistance (HOMA-IR), leptin and adiponectin was undertaken. Statistical analysis was performed using Wil-coxon signed rank test. Results: Mean age was 54.0 ± 7.0 years, with 8 (66.7%) female and 8 (66.7%) diabetic patients. Mean baseline values were: body mass index 35.3 ± 4.9 kg/ m2, waist circumference 110.8 ± 77 cm, HbA1c 6.6 ± 0.8%, HOMA-IR 77 ± 5.1, ALT 60.6 ± 18.5 U/L, leptin 27.9 ± 13.8 ng/mL and adiponectin 7.2 ±2 .6 μg/mL. Mean liver biopsy length was 14.9 ± 3.8 mm with a median NAS of 5.5 and hepatocellular ballooning present in every patient. Fibrosis stage prevalence was F1 58.3% (n=7), F2 8.3% (n=1) and F3 33.3% (n=4). Body mass index did not significantly change during therapy (P=0.35). 24 weeks of high-dose oral vitamin D3 supplementation increased 25-hydroxyvitamin D level from 63.3 ± 31.6 to 109.8 ± 15.